Dr. Carrie Haskell-Luevano loves being a researcher. As a professor and Philip S. Portoghese Endowed Chair in Chemical Neuroscience, she finds joy in teaching students and making discoveries alongside her laboratory staff. Read about the value she finds in her partnership with UMN Technology Commercialization.
New role becomes effective July 18, 2022.
The following students received American Foundation for Pharmaceutical Education (AFPE) Pre-Doctoral Fellowships for the 2022-2023 academic year. These prestigious competitive fellowships are awarded to "high performing students who possess the skill and aptitude to become outstanding scientists and leaders in the pharmaceutical industry, academia, and the government/nonprofit sectors.”
The results of Phase 2 clinical trials for glaucoma drug QLS-101 have demonstrated a favorable safety and tolerability profile, according to a news release by Qlaris Bio, which licensed the drug in 2019. A positive efficacy signal was also reported.
The Midwest Antiviral Drug Discovery (AViDD) Center is part of a network of nine national centers established in response to the public health emergency.
Thanks to a research collaboration between the Institute for Therapeutics Discovery & Development and Mayo Clinic, a drug that shows promise for glaucoma patients has moved to Phase I/II clinical trials.